Jaweher Bday | Cancer Research | Best Researcher Award

Published on by Oncology

Ms. Jaweher Bday | Cancer Research | Best Researcher Award 

PhD Student | Higher Institute of Biotechnology of Monastir | Tunisia

Ms. Jaweher Bday is a highly promising PhD researcher in biotechnology with a robust specialization in immuno-oncology, demonstrating strong potential and clear suitability for a Best Researcher Award through her scientific rigor, technical depth, and impactful research outputs. Her academic journey—from a bachelor’s degree in molecular and cellular biology, a research master’s in cell biology and physiology, to an ongoing PhD at the Higher Institute of Biotechnology of Monastir—illustrates continuous progression and dedication to cancer research. She has completed several competitive international research internships in leading laboratories in France, including the Bio PeroxIL Laboratory at the University of Burgundy and the INSERM U1307 Laboratory at the University of Nantes, enhancing her expertise in cell death mechanisms, tumor biology, and advanced molecular techniques. Her publication record is strong and growing, with peer-reviewed articles in recognized journals on topics such as arginase regulation in HPV infection, hybrid cell-death induction in breast cancer models, and the role of nitric oxide pathways in cervical carcinogenesis, along with an additional submitted manuscript on HPV circulating markers. Jaweher’s scientific maturity is evidenced by her active participation in conferences, including oral and poster presentations at national and international oncology and toxicology meetings, reflecting substantial dissemination of her research. Beyond laboratory excellence, she demonstrates leadership through major roles in the Tunisian Association of Biotechnology Students, including serving as President and spearheading scientific events and innovation-focused programs. Her teaching activities, spanning workshops, directed courses, and hands-on training, further showcase her commitment to academic development and knowledge transfer. Equipped with advanced laboratory skills, strong analytical proficiency using tools like FlowJo, ImageJ, SPSS, and GraphPad, along with extensive training in scientific writing, publishing, quality management, and pedagogy, she embodies the qualities of an emerging researcher with both scientific impact and community engagement. Overall, her achievements, productivity, international exposure, and leadership make her an excellent candidate for a Best Researcher Award.

Profile: ORCID

Featured Publications

  1. Souid, M., Bday, J., Souissi, S., Ghedira, R., Gabbouj, S., Shini-Hadhri, S., Toumi, D., Bergaoui, H., Zouari, I., Faleh, R., Zakhama, A., & Hassen, E. (2023). Arginase is upregulated in healthy women infected by oncogenic HPV types. Biomarkers, 28(7), 628–636.

  2. Bday, J., Souid, M., Pires, V., Gabbouj, S., Véjux, A., Lizard, G., & Hassen, E. (2025). Arginase activity inhibition with thymoquinone induces a hybrid type of cell death in MDA-MB-231 cell line. Journal of Biochemical and Molecular Toxicology, 39(2), e70130.

  3. Bday, J., Souid, M., Farhat, K. H., Macherki, Y., Ghedira, R., Gabbouj, S., Shini-Hadhri, S., Faleh, R., & Hassen, E. (2025). Involvement of endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) levels in precancerous and cancerous cervical lesions. Nitric Oxide, 159, 176–185.

  4. Souid, M., Ghedira, R., Bday, J., Gabbouj, S., Shini-Hadhri, S., Hajji, A., Faleh, R., & Hassen, E. (Under review). Human Papillomavirus-16 circulating markers distribution among unvaccinated women. Infectious Diseases Now.

  5. Bday, J., Souid, M., Pires, V., Véjux, A., Lizard, G., & Hassen, E. (2025). Hybrid cell-death mechanisms in breast cancer: Insights from thymoquinone-mediated arginase inhibition. Manuscript in preparation.

Ms. Jaweher Bday’s work advances immuno-oncology by uncovering novel cellular and molecular mechanisms that can drive more precise cancer diagnostics and targeted therapies. Her research contributes to global health by improving understanding of HPV-related cancers and breast cancer biology, supporting innovations that can shape future clinical and translational applications. Through scientific leadership, teaching, and community engagement, she helps strengthen research capacity and fosters the next generation of biotechnology innovators.

Ogadimma Arisukwu | cancer | Editorial Board Member

Published on by Oncology

Dr. Ogadimma Arisukwu | cancer | Editorial Board Member

Research Scholar | Landmark University | Nigeria

Dr. Ogadimma Arisukwu is an accomplished social scientist and lecturer at Landmark University, Omu-Aran, Nigeria, whose scholarship spans social policy, public health systems, community studies, and socio-cultural dynamics within African societies. His research examines the intersection of governance, health service delivery, livelihood realities, and culturally rooted behavioral responses, with a particular focus on how institutional structures shape societal well-being. Dr. Arisukwu’s work offers evidence-based insights into contemporary sociological challenges, including health insurance utilization, socio-cultural perceptions of reproductive technologies, and emerging threats such as employment scams that affect vulnerable populations. His publications demonstrate strong methodological rigor, integrating qualitative and quantitative approaches to understand lived experiences, inform policy reforms, and strengthen community resilience. As an active academic contributor, he has authored numerous peer-reviewed studies in reputable international journals, contributing to global debates on health equity, social justice, and cultural determinants of human behavior. Dr. Arisukwu engages in interdisciplinary collaborations with scholars across Nigeria and beyond, promoting research that bridges academic inquiry and practical societal needs. His work carries substantial societal relevance, supporting better-informed policymaking, advancing inclusive healthcare practices, and deepening understanding of cultural frameworks that shape public perception and behavior. Through sustained research productivity and community-centered academic engagement, he has established himself as a respected voice in sociology and social policy research. Dr. Arisukwu’s academic influence and research productivity are reflected in his metrics 212 citations, 31 documents, and an h-index of 9.

Profiles: Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Job scams in Ibadan (2024) Arisukwu, O., et al. (2024). Job advertisements and lived experiences of victims of job scams in Ibadan, Nigeria. International Journal of Sociology and Social Policy.
(Citations: 2)

2. NHIS–HMO healthcare perception (2023) Mkperedem, A. A., Ogunlade, P., Igbolekwu, C., Arisukwu, O., Owa, S. O., Afolabi, A. O., & Etta-Oyong, S. O. (2023). Healthcare service delivery perception among NHIS-HMO enrollees in Lagos hospitals. Humanities and Social Sciences Communications. (Citations: 2)

3. Religious & cultural interpretations of artificial insemination (2023) Authors include: Arisukwu, O., et al. (2023). Religious and cultural interpretations of artificial insemination in South-West Nigeria. AJOG Global Reports. (Citations: 4)

4. Attitudes of medical personnel in Lagos hospitals (2023) Mkperedem, A. A., Ogunlade, P., Igbolekwu, C., Arisukwu, O., Owa, S. O., Afolabi, A. O., & Etta-Oyong, S. O. (2023). Perception among NHIS–HMO enrolees of the attitudes of medical personnel during outpatient care in Lagos hospitals. International Journal of Environmental Research and Public Health, 20(2). https://doi.org/10.3390/ijerph20021218

5. Youth gambling in Nigeria (2021)

Adebisi, T., Alabi, O., Arisukwu, O., & Asamu, F. (2021). Gambling in transition: Assessing youth narratives of gambling in Nigeria. Journal of Gambling Studies. https://doi.org/10.1007/s10899-020-09982-x

Hifzur R Siddique | Cancer Science | Editorial Board Member

Published on by Oncology

Assist. Prof. Dr. Hifzur R Siddique | Cancer Science | Editorial Board Member

Assistant Professor | Aligarh Muslim University | India

Dr. Hifzur R. Siddique is a distinguished researcher and academic at Aligarh Muslim University, India, specializing in cancer biology, nanomedicine, stem cell research, chemoresistance mechanisms, and translational therapeutics. His work spans the synthesis and characterization of metal oxide nanoparticles with anticancer potential, epigenetic regulation in cancer, and preclinical evaluation of natural compounds like lupeol for chemotherapeutic applications. Dr. Siddique has contributed significantly to methodological advancements, including the use of Drosophila melanogaster models for DNA damage studies and luciferase-based reporter assays for kinase activity assessment. With a robust portfolio of 103 publications in high-impact journals, book chapters, and systematic reviews, he collaborates extensively with over 340 co-authors worldwide, reflecting his leadership in multidisciplinary cancer research. His studies not only advance fundamental understanding of tumor biology but also address translational challenges, bridging laboratory findings to clinical and societal impact. Dr. Siddique’s research has influenced global guidelines on rare malignancies such as NUT carcinoma and contributed to the development of nanocomposite-based therapeutic strategies. His work embodies a commitment to improving cancer outcomes, fostering innovation, and mentoring the next generation of scientists in oncology and biomedical sciences. Dr. Siddique’s academic influence and research productivity are reflected in his metrics 3,083 citations, 103 documents, and an h-index of 30.

Profiles: Google Scholar | Scopus | ORCID | LinkedIn

Featured Publications

Siddique, H. R., & Saleem, M. (2011). Beneficial health effects of lupeol triterpene: A review of preclinical studies. Life Sciences, 88(7-8), 285–293. [Cited by 477]

Siddique, H. R., & Saleem, M. (2012). Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: Preclinical and clinical evidences. Stem Cells, 30(3), 372–378. [Cited by 419]

Mishra, S. K., Siddique, H. R., & Saleem, M. (2012). S100A4 calcium-binding protein is key player in tumor progression and metastasis: Preclinical and clinical evidence. Cancer and Metastasis Reviews, 31(1), 163–172. [Cited by 212]

Siddique, H. R., Chowdhuri, D. K., Saxena, D. K., & Dhawan, A. (2005). Validation of Drosophila melanogaster as an in vivo model for genotoxicity assessment using modified alkaline Comet assay. Mutagenesis, 20(4), 285–290. [Cited by 146]

Fatma, H., Maurya, S. K., & Siddique, H. R. (2022). Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance. Seminars in Cancer Biology, 83, 166–176. [Cited by 136]

Jun Lu | Cancer | Editorial Board Member

Published on by Oncology

Prof. Jun Lu | Cancer | Editorial Board Member

Professor | Chengdu University of Traditional Chinese Medicine | China

Dr. Jun Lu is a distinguished researcher at Chengdu University of Traditional Chinese Medicine, China, specializing in cancer nanomedicine, biomaterials, and translational therapeutics. His work focuses on the design and development of multifunctional nanoplatforms, including engineered chitosan nanoparticles, aptamer-conjugated chemotherapeutics, and self-gelling biomaterials for applications in tumor therapy, wound healing, and infectious disease management. Dr. Lu integrates molecular biology, materials science, and bioengineering to advance innovative therapeutic strategies, such as modulating tumor microenvironments, orchestrating DNA damage pathways in colorectal carcinoma, and promoting MRSA-infected wound healing. He has authored 78 publications in high-impact journals including Journal of Translational Medicine, Chemical Engineering Journal, Carbohydrate Polymers, and Nano Research, reflecting strong expertise in nanobiotechnology and translational oncology. His extensive collaborations with over 380 co-authors worldwide demonstrate his leadership in multidisciplinary research networks, bridging fundamental science with clinical applications. Beyond academic contributions, Dr. Lu’s work has significant societal impact by enabling advanced therapies for cancer, infectious diseases, and tissue repair, providing novel solutions to global health challenges. His research emphasizes translational relevance and real-world applicability, contributing to safer, more effective, and innovative therapeutic modalities. Dr. Lu’s academic influence and research productivity are reflected in his metrics 2,421 citations, 78 documents, and an h-index of 24.

Profiles: Google Scholar | Scopus | ORCID 

Featured Publications

Lu, J., Zhang, H., Hou, J., Li, X., Hu, X., Hu, Y., Easton, C. D., Li, Q., Sun, C., … (2020). Efficient metal ion sieving in rectifying subnanochannels enabled by metal–organic frameworks. Nature Materials, 19(7), 767–774. Cited by: 495

Ni, S., Yao, H., Wang, L., Lu, J., Jiang, F., Lu, A., Zhang, G. (2017). Chemical modifications of nucleic acid aptamers for therapeutic purposes. International Journal of Molecular Sciences, 18(8), 1683. Cited by: 384

Lu, J., Jiang, F., Lu, A., Zhang, G. (2016). Linkers having a crucial role in antibody–drug conjugates. International Journal of Molecular Sciences, 17(4), 561. Cited by: 352

Tan, C. M., Therien, A. G., Lu, J., Lee, S. H., Caron, A., Gill, C. J., Lebeau-Jacob, C., … (2012). Restoring Methicillin-Resistant Staphylococcus aureus susceptibility to β-lactam antibiotics. Science Translational Medicine, 4(126), 126ra35.
Cited by: 328

Li, F., Lu, J., Liu, J., Liang, C., Wang, M., Wang, L., Li, D., Yao, H., Zhang, Q., Wen, J., … (2017). A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nature Communications, 8(1), 1390.
Cited by: 275

 

Ramon Mangues | Cancer | Best Research Article Award

Published on by Oncology

Prof. Dr. Ramon Mangues | Cancer | Best Research Article Award

Pharmacological Research | Institut de Recerca Sant Pau | Spain

Prof. Dr. Ramon Mangues Bafalluy, PharmD, PhD, is a distinguished Clinical Pharmacist and Biomedical Research Professor at the Institut de Recerca, Hospital de la Santa Creu i Sant Pau, where he leads the Consolidated Oncogenesis and Antitumor Drugs Group (GOA). A recognized authority in oncology, nanomedicine, and targeted drug delivery, he has made pioneering contributions to the development of therapeutic nanotechnologies and translational cancer research. Trained in pharmacy and clinical pharmacology, Dr. Mangues advanced his expertise in cancer biology through extensive postdoctoral research at the New York University Medical Center. His professional career spans key leadership roles within IIB Sant Pau, CIBER-BBN, and as Co-founder and Scientific Advisor of Nanoligent S.L., a spin-off dedicated to translating nanomedicine discoveries into clinical therapies. His research interests encompass nanoconjugates, protein-based nanoparticles for targeted drug delivery, immunotherapeutic strategies, preclinical drug development, and biomarker identification for improved cancer diagnosis and treatment. A strong advocate of collaborative science, he has partnered with leading clinical specialists and secured numerous competitive research grants, including participation in major European Union initiatives such as SAFE-N-MEDTECH, EuroTransBio, and H2020 programs. Holding multiple patents in nanomedicine, Dr. Mangues’s innovative work bridges the gap between molecular oncology and clinical application. As a mentor and academic leader, he has supervised numerous doctoral theses and authored an extensive body of publications that have shaped contemporary cancer nanotherapy approaches. His achievements have been recognized through prestigious distinctions for research excellence and international scientific leadership. Dr. Mangues’s enduring impact on biomedical innovation is evident through 7,280 citations, 154 documents, and an h-index of 42, underscoring his influential role in advancing nanomedicine and targeted cancer therapy research.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Merlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Attolini, C. S.-O., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., Clevers, H., Sancho, E., Mangues, R., & Batlle, E. (2011). The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell, 8(5), 511–524. Cited by: 1,145

2. Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde, A. (2016). Recombinant pharmaceuticals from microbial cells: A 2015 update. Microbial Cell Factories, 15(1), 33. Cited by: 445

3. Esteller, M., Gonzalez, S., Risques, R. A., Marcuello, E., Mangues, R., Germa, J. R., Herman, J. G., Capellà, G., & Peinado, M. A. (2001). K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. Journal of Clinical Oncology, 19(2), 299–304. Cited by: 335

4. Guerrero, S., Casanova, I., Farré, L., Mazo, A., Capellà, G., & Mangues, R. (2000). K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene. Cancer Research, 60(23), 6750–6756. Cited by: 325

5. Ventura, S., Zurdo, J., Narayanan, S., Parreño, M., Mangues, R., Reif, B., Chiti, F., Giannoni, E., Dobson, C. M., & Serrano, L. (2004). Short amino acid stretches can mediate amyloid formation in globular proteins: The Src homology 3 (SH3) case. Proceedings of the National Academy of Sciences, 101(19), 7258–7263. Cited by: 301

Dr. Sumaira Mubarik – Cancer Science – Best Researcher Award

Published on by Oncology

Dr. Sumaira Mubarik - Cancer Science - Best Researcher Award

University of Groningen - Netherlands

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Summaira Mubarik embarked on her academic journey with a strong foundation in mathematics, statistics, and computer science. She pursued her Bachelor of Science degree from Punjab University, Pakistan, specializing in Mathematics, Statistics, and Computer Science, which laid the groundwork for her future academic pursuits. Following this, she completed her FSc in Mathematics, Statistics, and Computer Science from BISE, Rawalpindi, Pakistan, further honing her analytical skills and preparing for advanced studies.

PROFESSIONAL ENDEAVORS:

Building upon her educational background, Mubarik pursued higher studies in statistics, earning her Master of Science degree from Arid Agriculture University Rawalpindi, Pakistan, in 2009. Subsequently, she completed her M.Phil, specializing in Statistics, from the same institution in 2012, where she conducted research on Quantile Regression Analysis of Blood Pressure levels for different factors of Adults under the supervision of Dr. Abdush Shakoor. These endeavors marked her entry into the realm of statistical research and analysis.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER SCIENCE

Mubarik's academic journey reached new heights when she pursued her PhD in Statistics at Wuhan University, China, from 2019 to 2021. Under the supervision of Prof. Chuanhua Yu, she delved into the domain of stochastic modeling and prediction of breast cancer risk transitions using the age-period-cohort framework. Her research not only showcased her expertise in applied statistics but also demonstrated a deep commitment to addressing critical issues in biostatistics and epidemiology.

IMPACT AND INFLUENCE:

Throughout her academic career, Mubarik has made significant contributions to the field of statistics, particularly in applied statistics, biostatistics, and disease modeling. Her research endeavors have the potential to impact public health policies and interventions aimed at mitigating the risk of breast cancer. Additionally, her work in stochastic mortality models and survival analysis holds promise for improving our understanding of disease progression and mortality patterns.

ACADEMIC CITATIONS:

Mubarik's research output has garnered attention and recognition within the academic community, as evidenced by her receipt of prestigious scholarships and awards. She was awarded the "Excellent International Student Award" from the Ministry of Education, China, in 2020, along with the Wuhan University Outstanding International Students Scholarship in 2020 and 2021 for her exceptional academic achievements.

LEGACY AND FUTURE CONTRIBUTIONS:

As an Assistant Professor at the University of Groningen, Netherlands, Mubarik continues to pursue her passion for statistics and research. Her expertise in pharma data science and statistics equips her to contribute significantly to the advancement of statistical methodologies in pharmaceutical research and healthcare. With a strong foundation in applied statistics and a focus on epidemiological modeling, Mubarik's future contributions hold the potential to shape the landscape of public health research and policy.

NOTABLE PUBLICATIONS

Estimating disparities of prostate cancer burden and its attributable risk factors for males across the BRICS-plus, 1990–2019: A comparable study of key nations with emerging economies. 2024 (1)

Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. 2024 (5)

Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. 2024 (1)

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. 2024 (4)

Temporal patterns of cancer burden in Asia, 1990–2019: a systematic examination for the Global Burden of Disease 2019 study 2024

Assoc Prof Dr.Tiruveedula Gopi Krishna – Cancer Science – Best Researcher Award

Published on by Oncology

Assoc Prof Dr.Tiruveedula Gopi Krishna - Cancer Science - Best Researcher Award

Adama Science and Technology University - Ethiopia

AUTHOR PROFILE

Google Scholar

Orcid

EARLY ACADEMIC PURSUITS

Dr. Tiruveedula Gopikrishna began his academic journey in the field of Computer Science and Engineering. His early academic pursuits laid the foundation for his future contributions in the realm of technology and information sciences.

PROFESSIONAL ENDEAVORS

Having demonstrated a keen interest in the field, Dr. Gopikrishna embarked on a professional journey that led him to the position of Assistant Professor and subsequently Associate Professor at Adama Science & Technology University in Ethiopia. His commitment to academia reflects in his multifaceted roles and responsibilities.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER SCIENCE

Dr. Gopikrishna's expertise encompasses a diverse range of subjects, including Data Science, Big Data, Artificial Intelligence, Machine Learning, Deep Learning, Distributed Systems, Data Warehousing, Data Mining, Cloud Computing, C, Python, C++, Java, Web Technologies, and SQL. His research focus extends to critical areas such as Big Data Analytics and Visualization, Software Testing Methodologies, Middleware, and the intersection of big data with cloud computing.

IMPACT AND INFLUENCE

Dr. Gopikrishna's impact is evident in the significant contributions he has made to the academic and research community. His influence extends beyond the classroom, shaping the minds of aspiring technologists and researchers under his guidance.

ACADEMIC CITES

The academic prowess of Dr. Gopikrishna is underscored by his extensive experience in teaching undergraduate and postgraduate subjects. He has been instrumental in guiding 56 undergraduate projects and supervising 4 master's degree theses, showcasing his commitment to fostering academic excellence.

LEGACY AND FUTURE CONTRIBUTIONS

As an Associate Professor, Dr. Gopikrishna has already established a legacy in academia. His dedication to shaping the next generation of tech professionals and researchers is evident. Looking forward, his future contributions are poised to further enrich the fields of Computer Science and Information Technology, leaving an indelible mark on the academic landscape.

NOTABLE PUBLICATIONS

An Improved Switch Migration Method Based Efficient Load Balancing for Multiple Controllers in Software Defined Network. 2023

DDoS Attack Detection and Classification Using Hybrid Model for Multi-controller SDN. 2023 (3)

Classification of Brain Tumor Types on Magnetic Resonance Images Using Hybrid Deep Learning Approach with Radial Basis Function Neural Network. 2022

Breast Cancer Classification from Mammogram Images Using Extreme Learning Machine-Based DenseNet121 Model. 2022 (5)

Designing and Developing Bilingual Chatbot for AssistingEthio-Telecom Customers on Customer Services. 2022

Advancements in Cancer Genomics Award

Published on by Oncology

Introduction: Embark on a journey of scientific excellence with the Advancements in Cancer Genomics Award, an accolade dedicated to recognizing pioneering contributions in the dynamic field of cancer genomics. This award celebrates individuals who have demonstrated outstanding innovation and impact in unraveling the complexities of cancer at the genomic level.

Award Eligibility: Open to researchers and professionals worldwide, regardless of age, the Advancements in Cancer Genomics Award seeks individuals with a proven track record of excellence in cancer genomics research. Eligible candidates must hold a minimum qualification of a doctoral degree and showcase significant contributions through impactful publications.

Evaluation Criteria: Candidates will be assessed based on the originality and significance of their work in cancer genomics, the quality of publications, and their overall impact on advancing our understanding of genomic mechanisms underlying cancer.

Submission Guidelines: Applicants are required to submit a comprehensive package, including a detailed biography, an abstract of their cancer genomics research, and supporting files that offer a deep dive into the methodology and outcomes of their work. Adherence to specified format guidelines is crucial for a successful submission.

Recognition and Community Impact: Beyond individual recognition, this award acknowledges the broader impact of awardees' contributions on the cancer genomics community. Recipients will be honored in prestigious events and publications, amplifying their influence in the scientific community.